Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dexibuprofen→

Dexibuprofen Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
51146-56-6
Molecular formula
C13H18O2
Molecular weight
206.28 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pharmacologically active S(+)-enantiomer of ibuprofen
Mechanism of action
A non-selective cyclo-oxygenase inhibitor that reduces prostaglandin synthesis, producing analgesic, anti-inflammatory and antipyretic effects; it also inhibits platelet aggregation.
Indications / reported uses
  • Symptomatic treatment of pain and inflammation in osteoarthritis
  • Primary dysmenorrhoea
  • Mild-to-moderate pain, including musculoskeletal pain, headache and toothache
  • Short-term symptomatic treatment of rheumatoid arthritis when disease-modifying therapy is not being considered; the cited UK SmPC includes adults and children/adolescents from 8 years

Sources: UK SmPC — Dexibuprofen 200 mg tablets (updated 6 Jun 2026) · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Non-steroidal anti-inflammatory drug (NSAID); pharmacologically active S(+)-enantiomer of ibuprofen

Mechanism of action

A non-selective cyclo-oxygenase inhibitor that reduces prostaglandin synthesis, producing analgesic, anti-inflammatory and antipyretic effects; it also inhibits platelet aggregation.

General use cases

  • Symptomatic treatment of pain and inflammation in osteoarthritis
  • Primary dysmenorrhoea
  • Mild-to-moderate pain, including musculoskeletal pain, headache and toothache
  • Short-term symptomatic treatment of rheumatoid arthritis when disease-modifying therapy is not being considered; the cited UK SmPC includes adults and children/adolescents from 8 years

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Dexibuprofen Environmental Risk Assessment (ERA) (the Dexibuprofen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.